Session » Spondyloarthritis Including Psoriatic Arthritis – Treatment III: Axial Spondyloarthritis (2028–2032)
- 4:00PM-4:50PM
-
Abstract Number: 2028
Predictors of Maintaining Inactive Disease After Etanercept Withdrawal, and Regaining Inactive Disease Status After Flare and Retreatment, in Adults with Non-radiographic Axial Spondyloarthritis: Results from RE-EMBARK
- 4:00PM-4:50PM
-
Abstract Number: 2029
Therapeutic Drug Monitoring Compared to Standard Treatment of Patients Starting Infliximab: Results from a Multicenter Randomized Controlled Trial of 400 Patients
- 4:00PM-4:50PM
-
Abstract Number: 2032
Treatment Response to Biological Disease-modifying Anti-rheumatic Drugs Is Associated with Favorable Changes of the Body Composition in Patients with Ankylosing Spondylitis
- 4:00PM-4:50PM
-
Abstract Number: 2030
Treatment with Selective Cyclooxygenase-2 Inhibitors Is Associated with Inhibition of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort
- 4:00PM-4:50PM
-
Abstract Number: 2031
Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis